The client had identified a potential company acquisition and required "top-level" operational analyses.

To better understand the target company's operations, the client engaged MattsonJack to perform the analyses. In addition, MattsonJack was asked to deliver the analyses under a tight timeline.

MattsonJack analyzed different operational aspects of the target company, including business unit operations; currently marketed products (indications, sales / physician prescription trends); products in development; and licensing deal terms with current partners, sales force infrastructure and selected financial analyses.

In addition, MattsonJack provided a long-range product forecast of all relevant therapeutic areas to supplement its strategic recommendations and items for the client's consideration regarding overall geographic, therapeutic (current and future products) and sales force "fit."

A leading European pharmaceutical company that had been an MattsonJack client for more than a decade retained MattsonJack to drive its growth initiatives. The company had no dedicated corporate development personnel.

MattsonJack approached the client's growth needs in two ways:

In-licensing

• Two deals were completed. While many other opportunities were identified, these became too problematic or expensive in the owners' opinion to execute.
• In response, MattsonJack initiated and organized a consortium of privately owned pharmaceutical companies in France, Germany, Italy, and Spain/Portugal. Other companies in the United Kingdom, Scandinavia, Benelux and Eastern Europe were considered and rejected. These companies agreed to share their pipelines and the cost of joint development
  

Out-licensing

• MattsonJack assumed responsibility for the identification of licensees for a unique NCE that was in Phase III in France.
• A U.S. firm licensed the compound for the United States and eventually for other countries.
• The product was developed and successfully launched. It reached $500 million in sales in the United States and elsewhere.
• Its indications have been broadened.

The client was considering its next growth initiative: the acquisition of a prescription pharmaceutical company with several products of interest — advantageous because the client needed more products to promote through its primary care division. One product of interest was the number-two supplement in its therapeutic class in the U.S. market.

The client retained MattsonJack to conduct commercial and scientific due diligence activities, including:

• forecasting the potential for thyroid and other current products
• assessing the potential for pipeline products
• working with the investment bank performing valuations
• assessing the quality of management and facilities

A privately held U.S. biotechnology firm had interesting drug targeting and development technology. It had developed a number of targets and some small molecule candidates, but it did not have sufficient capital to pursue these opportunities.

The client engaged MattsonJack to conduct the following commercial and scientific development activities:

• advise executive management on the best approach to seek additional capital through licensing and business development activities
• assess the potential of identifying a Japanese company as a prospective joint-development partner
• identify Japanese development partner(s)
• assist client in establishing productive business relationships in Japan that would lead to successful research and/or commercial collaborations

MattsonJack developed a business development strategy for Japan, matching the client's technology with Japanese companies that would be optimum partners.

Regular business trips were made to Japan during a two-year period and strong relationships were established with several Japanese companies that led to research and commercial agreements, including:

• the development of a lead candidate for peripheral neuropathies
• a multimillion-dollar research collaboration directed at two research programs

Following the restructuring of certain divisions, a European client needed help marketing and licensing a new proprietary compound. The client, a fully integrated subsidiary of a midsized international pharmaceutical company headquartered in Germany, produced an essential product and engaged in custom synthesis, development and manufacturing of APIs for third parties.

MattsonJack was engaged as the U.S. agent to represent the client within the industry, including pharmaceutical, dietary supplement and nutraceutical companies.

MattsonJack devised a market-entry strategy and has approached more than 50 selected companies to introduce the product's features and benefits.

As part of an ongoing, multiyear retainer relationship, MattsonJack:

• prepared product presentations
• identified and qualified potential licensees
• introduced the product opportunity and negotiated deal terms
• crafted deal structures and term sheets
• assisted the client in the finalization of supply and license agreements
• provided business development services, including expansion of fields of use